NO20020931L - Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger - Google Patents

Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger

Info

Publication number
NO20020931L
NO20020931L NO20020931A NO20020931A NO20020931L NO 20020931 L NO20020931 L NO 20020931L NO 20020931 A NO20020931 A NO 20020931A NO 20020931 A NO20020931 A NO 20020931A NO 20020931 L NO20020931 L NO 20020931L
Authority
NO
Norway
Prior art keywords
pyrrolo
nucleoside analogs
pyrimidine nucleoside
substituents
preparations
Prior art date
Application number
NO20020931A
Other languages
English (en)
Other versions
NO20020931D0 (no
Inventor
Guangyi Wang
Robert Tam
Zbigniew Pietrzkowski
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of NO20020931L publication Critical patent/NO20020931L/no
Publication of NO20020931D0 publication Critical patent/NO20020931D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

I Preparater og metoder for pyrrolo[2.3-d]pyrimidinnukleosid-analoger som har substituenter I C4' og C5' stillingene av ribofuranosegruppen er presentert. De foreliggende preparater viser, blant annet, anti-kreft og immunomodulerende effekter med redusert cytotoksisitet.
NO20020931A 1999-08-27 2002-02-26 Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger NO20020931D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15123399P 1999-08-27 1999-08-27
PCT/US2000/022674 WO2001027114A1 (en) 1999-08-27 2000-08-17 PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS

Publications (2)

Publication Number Publication Date
NO20020931L true NO20020931L (no) 2002-02-26
NO20020931D0 NO20020931D0 (no) 2002-02-26

Family

ID=22537871

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020931A NO20020931D0 (no) 1999-08-27 2002-02-26 Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger

Country Status (18)

Country Link
EP (1) EP1212326A4 (no)
JP (1) JP2003511454A (no)
KR (1) KR20020092904A (no)
CN (1) CN1384834A (no)
AU (1) AU769578B2 (no)
BR (1) BR0013642A (no)
CA (1) CA2381297A1 (no)
HR (1) HRP20020163A2 (no)
HU (1) HUP0301875A2 (no)
IL (1) IL147908A0 (no)
MX (1) MXPA02001753A (no)
NO (1) NO20020931D0 (no)
PL (1) PL354094A1 (no)
RU (1) RU2002103501A (no)
SI (1) SI20819A (no)
SK (1) SK1772002A3 (no)
WO (1) WO2001027114A1 (no)
ZA (1) ZA200201567B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101851241B (zh) * 2010-07-02 2012-05-23 西安交通大学 一种抗肿瘤化合物及其制备方法和其用途
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN102286048A (zh) * 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
RU2720811C2 (ru) * 2015-09-23 2020-05-13 Мерк Шарп И Доум Лимитед 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988338A (en) * 1974-04-24 1976-10-26 Wisconsin Alumni Research Foundation 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof

Also Published As

Publication number Publication date
EP1212326A4 (en) 2003-08-20
EP1212326A1 (en) 2002-06-12
IL147908A0 (en) 2002-08-14
WO2001027114A1 (en) 2001-04-19
AU769578B2 (en) 2004-01-29
HRP20020163A2 (en) 2004-02-29
AU7061800A (en) 2001-04-23
NO20020931D0 (no) 2002-02-26
HUP0301875A2 (hu) 2003-09-29
MXPA02001753A (es) 2002-10-23
BR0013642A (pt) 2002-05-07
JP2003511454A (ja) 2003-03-25
SI20819A (sl) 2002-08-31
SK1772002A3 (en) 2002-10-08
CA2381297A1 (en) 2001-04-19
PL354094A1 (en) 2003-12-29
ZA200201567B (en) 2003-07-30
CN1384834A (zh) 2002-12-11
RU2002103501A (ru) 2003-09-10
KR20020092904A (ko) 2002-12-12

Similar Documents

Publication Publication Date Title
NO20020931L (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
WO2002100354A3 (en) Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP2011499A3 (en) Pyrrolo[2,3d]Pyrimidine compositions and their use
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HUP0101564A2 (hu) Epotilon készítmények
SG149067A1 (en) IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
ES2118835T3 (es) 2-etil-1h-imidazo(4,5-c)quinolin-4-aminas antiviricas.
DK0603251T3 (da) 1-substituerede 1H-imidazol(4,5-c)quinolin-4-aminer, mellemprodukter og farmaceutiske sammensætninger
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
HUP0401777A3 (en) 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
NZ513450A (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
AU7776891A (en) 5-benzyl barbiturate derivatives
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
NO20061402L (no) Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
YU47802A (sh) Postupci i kompozicije za levovirin
ATE250603T1 (de) 1,8-naphthalimid imidazo(4,5,1-de)acridone mit antitumorwirkung
MY126526A (en) Pharmaceutical formulations
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application